







# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademerk Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington DC 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/438,392	11/12/1999	TAKASHI AOYAMA	2312-105	9249
6449	7590 02/10/2003			
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			EXAMINER	
			ZARA, JANE J	
WASHINGTON, DC 20005			ART UNIT	PAPER NUMBER
			1635	
		DATE MAILED: 02/10/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

Fle

# Office Action Summary

Application No. 09/438,392

Applicant(s)

Aoyama et al

Examiner

Jane Zara

Art Unit 1635



The MAILING DATE of this col	mmunication appears on the cover sheet with the correspondence address			
Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.				
	ons of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
mailing date of this communication.  - If the period for reply specified above is less than thir	ty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.			
- If NO period for reply is specified above, the maximus	n statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).			
	ths after the mailing date of this communication, even if timely filed, may reduce any			
Status	<i>n</i> .			
1) X Responsive to communication(s	s) filed on <u>Dec 20, 2002</u> .			
2a) This action is <b>FINAL</b> .	2b) 🔀 This action is non-final.			
	dition for allowance except for formal matters, prosecution as to the merits is practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims				
4) 💢 Claim(s) <u>67-83</u>	is/are pending in the application.			
4a) Of the above, claim(s)	is/are withdrawn from consideration.			
5)	is/are allowed.			
6) 💢 Claim(s) <u>67-75 and 77-83</u>	is/are rejected.			
7) 💢 Claim(s) <u>76</u>	is/are objected to.			
8)	are subject to restriction and/or election requirement.			
Application Papers				
9) The specification is objected to	by the Examiner.			
10) The drawing(s) filed on	is/are a) $\square$ accepted or b) $\square$ objected to by the Examiner.			
Applicant may not request that	any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) The proposed drawing correcti	on filed on is: a) $\square$ approved b) $\square$ disapproved by the Examiner.			
	are required in reply to this Office action.			
12) The oath or declaration is obje	cted to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 1	20			
13) Acknowledgement is made of	a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) □ All b) □ Some* c) □ No	one of:			
1. Certified copies of the pri	ority documents have been received.			
2. Certified copies of the pri	ority documents have been received in Application No			
	pies of the priority documents have been received in this National Stage he International Bureau (PCT Rule 17.2(a)).			
*See the attached detailed Office	action for a list of the certified copies not received.			
14) ☐ Acknowledgement is made of	a claim for domestic priority under 35 U.S.C. § 119(e).			
	a language provisional application has been received.			
15) Acknowledgement is made of	a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s)	4) T (Annaiss C (DTO 440) Danie No. ()			
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
Notice of Draftsperson's Patent Drawing Review     Information Disclosure Statement(s) (PTO-1449)				
3) [_] Information Disclosure Statement(s) (PTO-1449)	r apol (10/3) 0/ Otto).			

Fle

Application/Control Number: 09/438,392

Art Unit: 1635

#### **DETAILED ACTION**

Applicant's response filed 12-20-02 have been received and entered.

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

## Response to Arguments and Amendments

Applicant's arguments with respect to claims 67-83 have been considered but are moot in view of the new ground(s) of rejection.

### Withdrawn Rejections

Any rejections not repeated in this Office action are hereby withdrawn.

## New Rejections

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was

Art Unit: 1635

commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 67-75, 77-83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Louvion et al in view of Goff et al, the combination further in view of the combined teachings of Aoyama et al, Brasselman et al and Schena et al, Draper et al and Krebbers et al.

The claimed invention is drawn to a vector or isolated nucleic acid construct (and transgenic plants or plant cells comprising the nucleic acid construct), comprising an inducible transcription construct or system which controls the expression of an operably linked gene such as a selectable marker or reporter gene including luciferase or maize LC, or a gene which can promoter shoot regeneration, which inducible transcription system comprises, from 5' to 3', a constitutive or inducible promoter, nucleic acid encoding a DNA binding domain of LexA, nucleic acid encoding a VP16 transactivating domain, DNA encoding a regulatory domain of an estrogen receptor.

Louvion et al teach vectors comprising DNA sequences, from 5' to 3', encoding a constitutive promoter operably linked to a DNA binding domain of Gal 4, DNA encoding the transactivating domain of VP16, and DNA encoding the regulatory domain of an estrogen receptor (see especially figure 1 on page 130; text and Table I on page 131).



Art Unit: 1635

Louvion et al do not teach the Lex A DNA binding domain in an inducible transcription system, nor the operable linkage of nucleic acids encoding a gene which causes anthocyanin production such as maize LC, nor genes whose expression promotes shoot regeneration.

Goff et al teach the flexibility of gene control by utilizing DNA binding domains and LetA response elements from a variety of transcriptional activators, including the interchanging of sexA with GALA, in combination with VP16 as a tanscriptional activator. Goff et al generally teach the use of LexA or GALA DNA binding sites in combination with VP16 and a mammalian steroid hormone receptor binding domain, including the estrogen receptor binding domain, in an inducible transcription systems in plants. Goff et al teach vectors and isolated nucleic acids comprising a chemically inducible promoter, and further comprising a regulatory domain of a glucocorticoid and/or an estrogen receptor, a selectable marker such as an antibiotic or a herbicide resistant gene, a CaMV 35S promoter, the DNA-binding domain and upstream activating region of GAL4, DNA encoding the VP16 transactivating domain, the DNA binding domain of the LexA repressor, nucleic acids encoding luciferase and a gene of interest (See entire document, especially col. 1-3 and 9-14, and claims 1, 12 and 15).

Aoyama et al teach nucleic acid constructs in transgenic plants comprising an inducible transcription system controlling an operably linked reporter gene (luciferase), which transcription system comprises a constitutive or inducible promoter, the DNA binding domain of GALA, the transactivating domain of VP16 and the receptor domain of the mammalian hormone



Art Unit: 1635

glucocorticoid (see especially the text on page 605, figure 1 on page 606, text on page 608: i.e. section entitled *Responses to various glucocorticoids* and the experimental procedures described on page 610).

Braselmann et al teach an inducible transcription system comprising the DNA binding domain of GAL4, the transactivating domain of VP16, and the hormone binding domain of the estrogen receptor, and the application of such a mammalian hormone transcription induction system in cell types which do not express endogenous estrogen receptors, and which lack GAL4 binding activity (see the abstract and last two paragraphs of the introduction on page 1657, figure 1 on page 1658, figure 2 on page 1658, figure 5 on page 1660, and the text on pages 1660-1661).

Krebbers et al teach the expression and use of anthocyanin genes, including a nucleic acid encoding maize LC, for maintaining male sterility in plants (see especially the abstract, col 2-7, claim 1).

Draper et al teaches the expression of genes which can promote shoot regeneration, which genes include cell type specific, inducible promoters, which promoters are used in combination with marker genes to promote cell type specific expression in transgenic plants and high expression in plant cultures (see especially the abstract and examples 7-8, cols 23-25).

It would have been obvious to modify the vector of Louvian et al by exchanging the GAL4 binding domain with a lexA binding domain because the interchanging of these binding domains in transcription systems, and in combination with VP16, had been taught previously by Goff. One of ordinary skill in the art would have been motivated to utilize either GAL4 or lexA in

Art Unit: 1635

combination with VP16 as a transcriptional activator because it had been taught previously that the swapping of response elements and binding domains provides increased flexibility in controlling gene expression, as taught previously by Goff (see especially col. 9, lines 16-32). One of ordinary skill in the at would have expected to successfully utilize the combination of these components (e.g. either GAL4 or lexA in combination with VP16) in a transcription system because such routine exchanges had been taught previously by others in the art, including Goff. It would have been obvious to one of ordinary skill in the art to design and utilize an inducible transcription system in plants comprising a (constitutive or inducible) promoter, DNA encoding the GAL4 or LexA DNA binding domain, the VP16 transactivating domain and DNA encoding the regulatory domain of an estrogen receptor because inducible transcription systems comprising mammalian hormone regulatory domains in combination with either LexA or GAL4 binding sites and further comprising a VP16 transactivating domain have been utilized in various plant and animal cells which do not express endogenous hormone receptors, nor endogenous GAL4 or LexA activity, as taught previously by Louvion et al, Aoyama et al and Braselmann et al. One of ordinary skill in the art would have expected that a nucleic acid construct encoding, from 5' to 3', a constitutive promoter operably linked to a DNA binding domain of Gal 4 or LexA, DNA encoding the transactivating domain of VP16, and DNA encoding the regulatory domain of an estrogen receptor would provide for higher induction and expression of operably linked nucleic acid sequences encoding a marker gene because such increases in induction using this expression system have been taught previously by Louvion et al. One of ordinary skill in art would have been

Page 7

Application/Control Number: 09/438,392

Art Unit: 1635

motivated to design and utilize such a transcription induction system because host cells lacking

either endogenous hormone receptors or endogenous GALA or LexA activity have been found to

have low basal expression of genes operably linked to the transcription system, and the

combination of the DNA binding site, the hormone regulatory domain and the VP16

transactivation domain has been found to generate highly inducible gene products in appropriate

plant and animal host cells, as taught previously by Aoyama et al and Braselmann et al. One of

ordinary skill in the art would have expected that such highly inducible transcription systems

would provide high levels of expression of operably linked nucleic acids, including reporter or

selection genes such as antibiotic resistance genes or luciferase. One of ordinary skill in the art

would have been motivated to operably link a nucleic acid encoding a gene causing anthocyanin

production because anthocyanin production provides a color phenotype for selecting transformed

plants or plant cells harboring a gene causing its production, as taught previously by Krebbers et

al. One of ordinary skill in the art would have been motivated to induce the transcription of a

gene which promotes shoot regeneration because such genes are utilized for cell type specific

expression of operably linked genes, or for increased expression of operably linked genes in plant

tissue culture, as taught previously Draper et al.

Therefore the invention as a whole would have been prima facie obvious to one of

ordinary skill in the art at the time the invention was made.

Art Unit: 1635

#### Allowable Subject Matter

Claim 76 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is (703) 306-5820. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a

Art Unit: 1635

general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

RAM R. SHUKLA, PH.D PATENT EXAMINER